Charles Schwab Investment Management Inc Atreca, Inc. Transaction History

Charles Schwab Investment Management Inc

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 11, 2023	BUY	$0.91 - $1.82 $20,892 - $41,785	22,959 New	22,959 $26,000
Q2 2022 Aug 15, 2022	SELL	$1.56 - $3.25 $110,321 - $229,836	-70,719 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$1.61 - $5.2 $7,280 - $23,514	4,522 Added 6.83%	70,719 $225,000
Q2 2021 Aug 16, 2021	SELL	$7.82 - $13.8 $52,824 - $93,219	-6,755 Reduced 9.26%	66,197 $564,000
Q1 2021 May 17, 2021	BUY	$13.0 - $19.34 $23,660 - $35,198	1,820 Added 2.56%	72,952 $1.12 Million
Q4 2020 Feb 16, 2021	BUY	$13.03 - $17.09 $19,909 - $26,113	1,528 Added 2.2%	71,132 $1.15 Million
Q3 2020 Nov 13, 2020	BUY	$12.67 - $23.19 $253,146 - $463,336	19,980 Added 40.26%	69,604 $973,000
Q2 2020 Aug 14, 2020	BUY	$12.52 - $23.45 $164,713 - $308,508	13,156 Added 36.08%	49,624 $1.06 Million
Q1 2020 May 15, 2020	BUY	$11.4 - $27.28 $259,065 - $619,938	22,725 Added 165.36%	36,468 $604,000
Q3 2019 Nov 08, 2019	BUY	$10.42 - $22.04 $143,202 - $302,895	13,743 New	13,743 $169,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Charles Schwab Investment Management Inc, based on Form 13F filings with the SEC.

Stay updated on Charles Schwab Investment Management Inc with notifications on news.